Delivery Order SPE2DB20D1100-SPE2DB25FE6Y2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $11,411.43 under a firm fixed-price contract. The delivery order is non-set-aside and carries an ultimate completion date of September 4, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $19,792.71 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed price, competitively awarded contract was executed on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $16,453.58. This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, and no set-aside designation was used in the award. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a $3,729.39 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Actemra 200 mg/10 mL vials. The contract, which is a firm fixed price delivery order with an ultimate completion date of August 20, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). This award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a $8,210.25 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed-price contract, with an ultimate completion date of September 16, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made on a competitive, non-set-aside basis and represents a child delivery order under the company's larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $11,336.48 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes, with a completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct fulfillment order under AmerisourceBergen's broader contract vehicle with DLA. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This is a non-set-aside, competitively awarded contract with a firm fixed price ceiling value of $9,793.69 and a completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Actemra 162 mg/0.9 mL syringes, with a ceiling value of $23,369.56 and a firm fixed price structure. The delivery order is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. Performance is scheduled for...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE6Y2Delivery Order
The Defense Logistics Agency awarded a $27,454.56 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. The contract employs firm fixed price terms with an ultimate completion date of September 16, 2025, and utilizes no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999.999 billion ceiling value through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, with substantial experience supplying specialty medications, brand-name and generic drugs, and medical devices to military and veteran healthcare systems. The Actemra delivery supports the company's role as a primary vendor within the DLA's comprehensive global pharmaceutical supply program, which enables distribution of essential medical commodities to the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. This award reflects the company's established capability to meet federal procurement requirements through open competition and its status as a key provider within the DLA's medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.5k | 9/15/25 |